NasdaqGM:VERABiotechs
Assessing Vera Therapeutics (VERA) Valuation As Deerfield Ups Stake And FDA Priority Review Nears
Vera Therapeutics (VERA) is back on investors’ radar after Deerfield Management Company added 418,538 shares in the fourth quarter, as the market watches an FDA priority review decision for lead drug candidate atacicept.
See our latest analysis for Vera Therapeutics.
At a share price of $39.96, Vera’s recent 7 day share price return of 2.54% sits against a 30 day share price return decline of 5.35% and a 90 day share price return decline of 17.27%. The 1 year total shareholder return of...